Five years ago, a booklet label on a pharmaceutical product was a solution to an exceptional packaging problem, typically a small primary container or a multilingual export requirement. Today it is becoming the default format across a growing number of pharmaceutical applications, not because the containers have changed, but because the information load they must carry has grown substantially in a short period. The drivers are regulatory, and they are accumulating.
What the Pharmaceutical Label Must Now Carry
The Human Medicines Regulations 2012 set the minimum mandatory information for any medicine placed on the UK market: the product name, strength, pharmaceutical form, active ingredients in INN format, batch number, expiry date, storage conditions, marketing authorisation holder details, and the MA number. All of it must be legible at a minimum font size equivalent to 7 points. Braille is mandatory for all medicines handled directly by patients. And since January 2025, all products for the GB market must carry clearly legible “UK Only” labelling under the Windsor Framework.
For medical devices placed on the GB market alongside or within the same product family, the Unique Device Identifier must appear in a 2D data matrix code. Where a product is dual-marked for both GB and EU markets, both the UK Responsible Person and EU Authorised Representative details must appear. The MHRA’s post-market surveillance regulations, in force from June 2025, require that labels support full supply chain traceability referencing. That is a substantial amount of information for a container that may be a 5ml vial, a blister strip, or a pre-filled syringe.
Why Standard Label Formats Are No Longer Sufficient
The MHRA best practice guidance is explicit: font size must not be reduced below the 7-point minimum to accommodate additional information. The solution to a label space problem is not smaller text; it is a different label format. For a vial with a nominal volume of 10ml or less, a reduced information set is permitted on the primary container under Regulation 257 of the HMRs, but the full information set must still appear on the outer packaging. Where the primary container is presented without outer packaging, the full set must appear on the primary label. And for many pharmaceutical products in 2026, the full set no longer fits on a single-panel label at compliant font sizes.
Booklet labels allow pharmaceutical manufacturers to carry the complete mandatory information set on the primary container within the existing packaging footprint. The outer face of the booklet carries the most critical information: product name, strength, route of administration, batch number, expiry date, and the data matrix code. The inner pages carry the extended content: full multilingual declarations, detailed storage and handling instructions, contraindication summaries, and the “UK Only” statement where space on the outer face is constrained. Modern booklet label constructions hold up to 32 pages and are engineered to withstand sterilisation, cold chain temperature cycling, and the handling conditions of clinical environments.
The Operational Case
The shift to booklet labels also has an operational dimension. A label format that can accommodate regulatory changes through inner page updates, rather than full outer label redesigns, reduces the per-change cost of label management over the product lifecycle. In a regulatory environment where pharmaceutical labelling obligations have changed significantly in three consecutive years, with the Windsor Framework, UDI requirements, and post-market surveillance rules all arriving in quick succession, that operational flexibility is commercially material.
